351 related articles for article (PubMed ID: 19423648)
1. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases.
Daïen CI; Monnier A; Claudepierre P; Constantin A; Eschard JP; Houvenagel E; Samimi M; Pavy S; Pertuiset E; Toussirot E; Combe B; Morel J;
Rheumatology (Oxford); 2009 Aug; 48(8):883-6. PubMed ID: 19423648
[TBL] [Abstract][Full Text] [Related]
2. Comment on: Sarcoid-like granulomatosis in patients treated with tumour necrosis factor blockers: 10 cases.
Massara A; Cavazzini L; La Corte R; Trotta F
Rheumatology (Oxford); 2010 May; 49(5):1019-21; author reply 1021-2. PubMed ID: 20056768
[No Abstract] [Full Text] [Related]
3. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series.
Toussirot E; Berthelot JM; Pertuiset E; Bouvard B; Gaudin P; Wendling D; le Noach J; Lohse A; Lecuyer E; Cri L
J Rheumatol; 2009 Nov; 36(11):2421-7. PubMed ID: 19797509
[TBL] [Abstract][Full Text] [Related]
4. Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases.
Toussirot E; Pertuiset E; Kantelip B; Wendling D
Clin Exp Rheumatol; 2008; 26(3):471-5. PubMed ID: 18578973
[TBL] [Abstract][Full Text] [Related]
5. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.
Mohan N; Edwards ET; Cupps TR; Slifman N; Lee JH; Siegel JN; Braun MM
J Rheumatol; 2004 Oct; 31(10):1955-8. PubMed ID: 15468359
[TBL] [Abstract][Full Text] [Related]
6. New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication.
Tong D; Manolios N; Howe G; Spencer D
Intern Med J; 2012 Jan; 42(1):89-94. PubMed ID: 22389903
[TBL] [Abstract][Full Text] [Related]
7. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
[TBL] [Abstract][Full Text] [Related]
8. [Sarcoid-like granulomatosis in patients treated with anti-TNFα].
Petrovici A; Kaiser MJ; Louis R; Nguyen Dang D
Rev Med Liege; 2016 Mar; 71(3):124-8. PubMed ID: 27311243
[TBL] [Abstract][Full Text] [Related]
9. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
[TBL] [Abstract][Full Text] [Related]
10. [Pulmonary sarcoidosis developing during treatment with etanercept].
Kerjouan M; Jouneau S; Lena H; Luraine R; Desrues B; Delaval P
Rev Mal Respir; 2011 Mar; 28(3):360-4. PubMed ID: 21482342
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor-alpha antagonist-induced sarcoidosis.
Clementine RR; Lyman J; Zakem J; Mallepalli J; Lindsey S; Quinet R
J Clin Rheumatol; 2010 Sep; 16(6):274-9. PubMed ID: 20808167
[TBL] [Abstract][Full Text] [Related]
12. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy.
Lozeron P; Denier C; Lacroix C; Adams D
Arch Neurol; 2009 Apr; 66(4):490-7. PubMed ID: 19364934
[TBL] [Abstract][Full Text] [Related]
13. Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge.
van der Stoep D; Braunstahl GJ; van Zeben J; Wouters J
J Rheumatol; 2009 Dec; 36(12):2847-8. PubMed ID: 19966199
[No Abstract] [Full Text] [Related]
14. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases.
Hernández MV; Sanmartí R; Cañete JD; Descalzo MA; Alsina M; Carmona L; Gomez-Reino JJ;
Arthritis Care Res (Hoboken); 2013 Dec; 65(12):2024-31. PubMed ID: 23926075
[TBL] [Abstract][Full Text] [Related]
15. [Alopecia areata during anti-TNF alpha therapy: Nine cases].
Le Bidre E; Chaby G; Martin L; Perrussel M; Sassolas B; Sigal ML; Kaassis C; Lespessailles E; Nseir A; Estève E
Ann Dermatol Venereol; 2011; 138(4):285-93. PubMed ID: 21497255
[TBL] [Abstract][Full Text] [Related]
16. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.
Hochberg MC; Lebwohl MG; Plevy SE; Hobbs KF; Yocum DE
Semin Arthritis Rheum; 2005 Jun; 34(6):819-36. PubMed ID: 15942917
[TBL] [Abstract][Full Text] [Related]
17. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up.
Molloy ES; Langford CA; Clark TM; Gota CE; Hoffman GS
Ann Rheum Dis; 2008 Nov; 67(11):1567-9. PubMed ID: 18677012
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases.
Dhaille F; Viseux V; Caudron A; Dadban A; Tribout C; Boumier P; Clabaut A; Lok C
Dermatology; 2010; 220(3):234-7. PubMed ID: 20185892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
